MDxHealth is trading at $0.17, up 5.43% in pre-market, with no new company-specific announcement identified to explain the rise. - The latest releases concern preliminary third-quarter revenue and suspended full-year guidance, announced October 15. - A results release is scheduled for November 12. Major U.S. indices were higher, but available evidence does not establish they drove the move; no reliable pre-market volume figure was available.